Unrestricted Utilization of Sirolimus-Eluting Stents Compared with Conventional Bare Stent Implantation in the "Real World": The Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry

Circulation

Volumn 109, Issue 2, 2004, Pages 190-195

  Lemos, Pedro A ^a   Serruys, Patrick W ^a   Van Domburg, Ron T ^a   Saia, Francesco ^a   Arampatzis, Chourmouzios A ^a   Hoye, Angela ^a   Degertekin, Muzaffer ^a   Tanabe, Kengo ^a   Daemen, Joost ^a   Liu, Tommy K K ^a   McFadden, Eugene ^a   Sianos, Georgios ^a   Hofma, Sjoerd H ^a   Smits, Pieter C ^a   Van Der Giessen, Willem J ^a   De Feyter, Pim J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angioplasty; Restenosis; Revascularization; Stents

Indexed keywords

CLOPIDOGREL; RAPAMYCIN;

ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CAUSE OF DEATH; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG FATALITY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTENOSIS; SAFETY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; FEMALE; HEART DISEASES; HUMANS; MALE; NETHERLANDS; REGISTRIES; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 9144255404     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000109138.84579.FA     Document Type: Article

References (10)

1. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007-2011.
2. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
3. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
4. Degertekin M, Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation. 2002;106:1610-1613.
5. Lemos PA, Saia F, Ligthart JMR, et al. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation. 2003;108:257-260.
6. Lemos PA, Lee C, Degertekin M, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cordial. 2003;41:2093-2099.
7. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol. 2001;37:2239i-lxvi.
8. Ruygrok PN, Melkert R, Morel MA, et al. Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators. J Am Coll Cardiol. 1999;34:1507-1511.
9. Degertekin M, Regar E, Tanabe K, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol. 2003;41:184-189.
10. Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2003;107:24-27.